Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday

Key Points

• Monte Rosa Therapeutics (NASDAQ: GLUE) is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.31) per share and revenue of $7.23 million.
• In its last earnings report on May 8th, the company reported earnings of $0.57 per share, exceeding expectations significantly and generating revenue of $84.93 million.
• Monte Rosa Therapeutics has experienced recent changes in institutional investor holdings, with significant purchases, including a 122.7% increase in shares owned by Goldman Sachs Group Inc.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $7.23 million for the quarter.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.81. The company had revenue of $84.93 million during the quarter, compared to analysts' expectations of $13.57 million. Monte Rosa Therapeutics had a net margin of 3.86% and a return on equity of 2.65%. On average, analysts expect Monte Rosa Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Monte Rosa Therapeutics Stock Performance

Shares of NASDAQ:GLUE opened at $4.38 on Thursday. The firm's 50 day simple moving average is $4.99 and its 200-day simple moving average is $5.18. Monte Rosa Therapeutics has a one year low of $3.50 and a one year high of $12.40. The firm has a market cap of $269.41 million, a PE ratio of 54.76 and a beta of 1.42.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GLUE. Acadian Asset Management LLC purchased a new position in Monte Rosa Therapeutics during the first quarter valued at approximately $76,000. Goldman Sachs Group Inc. boosted its position in Monte Rosa Therapeutics by 122.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company's stock valued at $1,652,000 after acquiring an additional 196,238 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in Monte Rosa Therapeutics during the 1st quarter valued at $1,065,000. 79.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded Monte Rosa Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.